BUZZ-Aeterna Zentaris Inc: To open at record low after FDA rejection
** Canadian company's U.S.-listed shares set to open down 53 pct at a record low of 59 cents
** Says U.S. Food and Drug Administration rejected its experimental growth hormone diagnostic test
** FDA asks Aeterna to conduct a new trial to demonstrate the effectiveness of macimorelin, the company's experimental test designed to determine if adults' pituitary glands are secreting enough growth hormone
** Up to Wednesday's close, stock had fallen 7 pct this year
© Thomson Reuters 2017 All rights reserved.